Stock Pulse
Vertex Pharmaceuticals (VRTX) recently outperformed the S&P 500, closing at $509.47 [1]. The company launched two new therapies, Alyftrek and Journavx, expanding its CF treatment options and entering the pain management market [5]. Vertex also received European Commission approval to expand the use of its cystic fibrosis drug, Kaftrio, to a wider patient population [10]. While upcoming Q1 2025 earnings are projected to show a year-over-year decline in EPS, revenue is expected to increase, with strong full-year projections [1], [6]. Although analysts have lowered short-term EPS estimates and the stock's Forward P/E ratio is higher than its industry average [1], one DCF model suggests the stock is significantly undervalued [7]. Potential risks include lowered analyst expectations and high valuation, while opportunities exist in new therapies and market expansion.